The energetics of reserpine binding to the bovine adrenal biogenic amine transporter suggest that H+ ion translocation converts the transporter to a form which binds reserpine essentially irreversibly. Reserpine binding to bovine adrenal chromaffin granule membrane vesicles is accelerated by generation of a transmembrane pH difference (delta pH) (interior acid) or electrical potential (delta psi) (interior positive). Both components of the electrochemical H+ potential (delta mu H+) must be dissipated to block reserpine binding, and generation of either one stimulates the binding rate. Reserpine binding is less dependent than amine transport on the delta pH, suggesting that translocation of fewer H+ ions is required to expose the high-affinity site than are required for net transport. Bound reserpine dissociates very slowly, if at all, from the transporter. Binding is stable to 1% cholate, 1.5% Triton X-100, 1 M SCN-, and 8 M urea, but sodium dodecyl sulfate (0.035%) and high temperatures (100 degrees C) released bound reserpine, indicating that binding is noncovalent. The results raise the possibility that the transporter, by translocating one H+ ion outward down its concentration gradient, is converted to a form that can either transport a neutral substrate molecule inward or occlude reserpine in a dead-end complex.

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi00455a002DOI Listing

Publication Analysis

Top Keywords

reserpine binding
20
energetics reserpine
8
binding
8
chromaffin granule
8
biogenic amine
8
amine transporter
8
reserpine
8
binding bovine
8
bovine adrenal
8
potential delta
8

Similar Publications

Antifibrotic potential of reserpine (alkaloid) targeting Keap1/Nrf2; oxidative stress pathway in CCl-induced liver fibrosis.

Chem Biol Interact

February 2025

Centre of Excellence in Molecular Biology, University of the Punjab, Thokar Niaz Baig, Lahore, 53700, Pakistan; Applied and Functional Genomics Lab, Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan. Electronic address:

The death rate due to liver cancer approaches 2 million annually, the majority is attributed to fibrosis. Currently, there is no efficient, safe, non-toxic, and anti-fibrotic drug available, suggesting room for better drug discovery. The current study aims to evaluate the anti-fibrotic role of reserpine, an alkaloid plant compound against CCl-induced liver fibrosis.

View Article and Find Full Text PDF

The study aims to elucidate the pharmacological mechanism of Rauvolfia tetraphylla against breast cancer through a comprehensive, multi-faceted approach. This includes molecular docking, molecular dynamics, and experimental validation. Initial screening via ADME analysis and network pharmacology identified key compounds and potential targets.

View Article and Find Full Text PDF

Insecticidal potential of seven commonly available alkaloids against melon thrips (Thrips palmi Karny) was investigated through in vivo experiments and the bioactivity was explained via in silico approaches. In vivo screening showed highest mortality of T. plami larvae for reserpine (43%), closely followed by tropinone (41%) after 24 h of incubation.

View Article and Find Full Text PDF
Article Synopsis
  • * The study utilized in-silico modeling, in-vitro assays to determine the effectiveness of six anti-virulence compounds, and in-vivo testing through larvicidal activity against HvKp.
  • * Results indicated that linoleic acid emerged as the most promising compound for anti-virulence therapy, showing some activity in vivo, while other compounds did not demonstrate inhibitory effects against the targeted hypervirulence genes.
View Article and Find Full Text PDF

SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile.

Front Pharmacol

September 2024

The Guangdong Provincial Key Laboratory of Cardiovascular Drug R and D Enterprises, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, Guangdong Province, China.

Article Synopsis
  • Esketamine is the first fast-acting antidepressant approved by the FDA but has limited use due to addiction risks; SAL0114 is a new formulation aiming to improve safety and efficacy by combining deuterated dextromethorphan with bupropion.
  • Research methods included binding assays to evaluate the effects of deuteration, stability tests in mice, and various animal models to assess antidepressant effects.
  • Results showed that deuterated dextromethorphan had double the metabolic stability of regular dextromethorphan and worked synergistically with bupropion, leading to superior effectiveness in treating depression.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!